A Newark vaccine company will spend $8 million to expand in Delaware, adding 63 jobs over the next three years. Uvax Bio, considered an early stage biopharmaceutical company with cutting-edge vaccine platform technology, has been headquartered in Newark since 2018. where it has five employees. Its platform has produced both COVID-19 and HIV-1 vaccine candidates. The new positions will …